Imprime PGG: Additional Phase Ib/IIa data

A retrospective subgroup analysis of 11 patients with wild-type K-Ras mCRC from the second arm of an open-label, dose-escalation Phase Ib/IIa trial showed that 2, 4 and 6 mg/kg Imprime PGG plus Erbitux cetuximab as second- or third-line therapy produced a 46% ORR vs. a historical ORR of 17% for Erbitux alone. Additionally, rates of stable disease and disease control for Imprime PGG plus Erbitux were 36% and 82%, respectively, vs. historical rates of 49% and 66% for Erbitux alone. Median PFS was 24 weeks for Imprime PGG plus Erbitux vs. a historical PFS of 11 weeks for Erbitux alone. Data were presented at the European Society for Medical Oncology meeting in Milan. ...